At the ANA Annual Meeting last year in San Diego, breakthrough therapies with antisense oligonucleotides garnered the most interest. Attendees were amazed at seeing video of children with spinal muscular atrophy up and out of wheelchairs. M. Elizabeth Ross, MD, PhD, Chair of the ANA Scientific Program Advisory Committee (SPAC) and Director of the Center for Neurogenetics at Weill Cornell Medicine, offers her perspective on what will generate the most excitement at the ANA meeting this October in Atlanta: Preview of a Landmark Year
